The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

• প্রধান লেখক: Ronald G. Hall (লেখক), Travis J. Cole (লেখক), Chip Shaw (লেখক), Carlos A. Alvarez (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: MDPI AG, 2022-02-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

(1) Background: Fidaxomicin has been shown to significantly reduce <i>Clostridioides difficile</i> infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question....